ClinicalTrials.gov
ClinicalTrials.gov Menu

Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00655694
Recruitment Status : Completed
First Posted : April 10, 2008
Last Update Posted : June 4, 2015
Sponsor:
Information provided by:
Imperial College London

April 4, 2008
April 10, 2008
June 4, 2015
Not Provided
September 2007   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00655694 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)
A Non Interventional Study to Asses the Utility of Genomic/ Proteomic/ Metabonomic Profiling Approaches to the Classification and Pathological Basis of Inflammatory Lung Disease in Smokers, and Ex-smokers vs. Non-smokers and Asthmatics

Chronic obstructive pulmonary disease (COPD) is a chronic disease characterized by progressive airflow obstruction, chronic cough and dyspnoea in advanced stages.

Techniques such as genomics, proteomics and metabonomics, Technologies that aim to identify and quantify the dynamic set of all small molecules and metabolites present in an organism or a biological sample, offer the prospect of efficiently distinguishing individuals with particular diseases. The advantages of proteomics and metabonomics is that it can be carried out on a standard preparation of serum, plasma or urine, circumventing the need for specialist preparation of cellular mRNA required for genomics This methodology is based on mass spectrometry (MS), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) to analyze metabolites. High-performance liquid chromatography (HPLC) may also be applied. Several peak alignment algorithms have been developed to match the chromatograms before applying pattern recognition. Based on the pattern recognition, several potential biomarkers may be found and further identified by MS.. Finally, a number of potential biomarkers will be identified for distinguishing asthma and COPD.

We hope to develop a better understanding of lung disease. Information from these studies will only be used for research purposes, to help develop safer and more effective treatments for asthma and COPD.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Pulmonary Disease, Chronic Obstructive
Procedure: sputum, blood, urine, exhaled breath, lung function
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
September 2007
September 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Inclusion Criteria - Healthy non-smokers

    • Non-smoking volunteer aged 40 -75 years (age matched to COPD patients)
    • Normal spirometry (FEV1/FVC ratio >70% and FEV1>80% predicted)
    • Subjects are able to give informed consent Inclusion Criteria-COPD patients (stage 2-3 according to the GOLD guidelines)
    • Current and/or ex-smokers with no less than 10 pack-year smoking history aged 40-75 years
    • 30% FEV1 < 80% of predicted (the upper value is a postbronchodilator value)
    • FEV1/FVC < 70%
    • Stable COPD (no chest infection requiring antibiotics and/ or oral steroids in the past 2 months)
    • Long-acting beta2-agonists and long-acting antimuscarinic bronchodilators need to be stopped at least 8 hours before the study visit
    • The subjects are able to give informed consent
  • Inclusion Criteria - healthy smokers

    • Current smokers aged 40 -75 years (age matched to COPD patients)
    • Normal spirometry (normal FEV1/FVC ratio >70% and FEV1>80% predicted)
    • Subjects are able to give informed consent
  • Inclusion Criteria - asthmatics

    • Non-smoking asthma patients aged 40 -75 years (age matched to COPD patients)
    • Normal spirometry (normal FEV1/FVC ratio >70% and FEV1>80% predicted)
    • Subjects are able to give informed consent

Exclusion Criteria:

  • Exclusion Criteria - Healthy non-smokers

    • Chest infection that required treatment with antibiotics within the last 4 weeks
    • Subjects who have received research medication within the previous one month
    • Subjects unable to give informed consent
    • Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Exclusion Criteria-COPD patients
    • Bronchodilator reversibility > 12%
    • Chest infection that required treatment with antibiotics within the last 4 weeks
    • Subjects who have received research medication within the previous one month
    • Subjects unable to give informed consent
    • Patients with significant co-morbidities including any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study as judged by the investigator
    • Any other respiratory disease, which is considered by the investigator to be clinically significant
  • Exclusion Criteria - healthy smokers

    • Chest infection that required treatment with antibiotics within the last 4 weeks
    • Subjects who have received research medication within the previous one month
    • Subjects unable to give informed consent
  • Exclusion Criteria - asthmatics

    • Chest infection that required treatment with antibiotics within the last 4 weeks
    • Patients with significant co-morbidities as judged by the investigator
    • Subjects who have received research medication within the previous one month
    • Subjects unable to give informed consent
Sexes Eligible for Study: All
35 Years and older   (Adult, Older Adult)
Not Provided
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00655694
05/Q0410/97
Not Provided
Not Provided
Not Provided
Not Provided
Imperial College London
Not Provided
Principal Investigator: Sergei A Kharitonov, MD PhD National Heart and Lung Institute
Imperial College London
April 2008